HeraMED Raises $3.2M to Accelerate US Digital Maternity Care Rollout
HeraMED Limited (ASX: HMD) has completed a $3.2 million capital raising to fund commercial deployments across the US, Australia, and Europe. The placement attracted participation from new institutional and sophisticated investors alongside existing shareholders, demonstrating market confidence as the digital maternity care platform transitions from development to commercial execution.
The placement involved issuing 80 million new shares at $0.04 per share, representing a 7% discount to the last traded price of $0.043 before the company entered a trading halt on 22 January 2026. The issue price aligns with the 15-day volume-weighted average price, suggesting the discount was within market expectations rather than a steep dilution.
The timing is notable given HeraMED’s existing commercial agreements with Lee Health and Philips, positioning the company to deploy capital directly into revenue-generating activities rather than early-stage development. With partnerships already secured, the capital provides runway for broader market penetration as demand for digitally enabled maternity care solutions builds across fragmented healthcare systems.
Placement structure and timeline
The capital raising will be completed through a two-tranche structure to manage shareholder dilution and meet ASX Listing Rule requirements.
| Tranche | Shares Issued | Listing Rule | Settlement Date | Trading Date |
|---|---|---|---|---|
| Tranche 1 | 41.3 million | 7.1 & 7.1A | 3 February 2026 | 4 February 2026 |
| Tranche 2 | 38.7 million | Subject to approval | 23 March 2026 | 24 March 2026 |
Tranche 1 utilises the company’s existing placement capacity under ASX Listing Rules 7.1 (38.3 million shares) and 7.1A (2.96 million shares), allowing immediate settlement without shareholder approval. Tranche 2 requires shareholder endorsement at a meeting scheduled for 16 March 2026.
Key placement details include:
- Non-Executive Director Sharon Howell participating with $57,500 in Tranche 2, signalling board confidence in the commercial strategy
- Westar Capital Limited and Shares in Value Pty Ltd acting as Joint Lead Managers, with Candour Advisory Pty Ltd as co-manager and book runner
- Lead Managers receiving a 6% fee plus 15 million options (exercise price $0.06, three-year expiry) subject to shareholder approval
Director participation, while modest in dollar terms, provides a positive signal that internal stakeholders are backing the deployment strategy with personal capital.
When big ASX news breaks, our subscribers know first
What is HeraMED and why does digital maternity care matter?
HeraMED operates at the intersection of telehealth expansion and women’s health modernisation, developing technology to address fragmented maternity care delivery. The company’s HeraCARE platform combines hardware (the HeraBEAT foetal and maternal heart rate monitor) with cloud-based software to enable hybrid maternity care, where in-home monitoring is integrated with clinical oversight.
The platform allows expectant mothers to conduct foetal and maternal heart rate monitoring at home, transmitting data to healthcare providers through the cloud. This model aims to reduce the number of hospital visits required during pregnancy while improving early detection of potential complications. HeraBEAT is described as clinically validated, suggesting it has undergone testing to demonstrate accuracy comparable to traditional in-clinic monitoring equipment.
The problem being addressed centres on inefficiencies in traditional maternity care models. Pregnant women typically require frequent in-person consultations throughout pregnancy, creating access barriers for those in regional areas and adding cost to healthcare systems. Remote monitoring solutions can potentially improve outcomes by enabling more frequent data collection between visits, allowing clinicians to identify concerning trends earlier than the standard consultation schedule permits.
From an investment perspective, HeraMED is positioned within the broader digital health theme, specifically targeting the women’s health segment. Market tailwinds include growing acceptance of telehealth post-pandemic, rising healthcare costs driving demand for scalable solutions, and increasing focus on maternal health outcomes. The company’s platform targets health systems, private clinics, and digital health platforms rather than direct-to-consumer sales, suggesting a B2B2C model where HeraMED partners with healthcare providers who then deploy the technology to their patient populations.
Commercial momentum and use of funds
HeraMED’s existing commercial agreements provide validation of the platform’s market fit. Partnerships with Lee Health (a Florida-based health system) and Philips (global health technology company) demonstrate that established healthcare organisations are willing to integrate the HeraCARE platform into their care delivery models. The announcement references a “growing pipeline” of additional health systems and partners, suggesting early traction is generating further interest.
Managing Director and CEO Anoushka Gungadin framed the capital raising within this commercial context:
“We are pleased with the strong interest shown by new institutional and sophisticated investors, reinforcing the progress HeraMED has made in advancing its commercial strategy. HeraMED is gaining momentum with key initial commercial agreements now in place with Lee Health and Philips, and a growing pipeline of health systems and partners. Our seasoned team brings proven experience to capitalise on the shift in women’s digital health. This capital raise positions the Company for broader commercial deployment, particularly in the U.S., where demand for scalable, digitally enabled maternity and women’s health solutions continues to build, driven by long-standing gaps in care and fragmented solutions.”
The proceeds from the placement will be deployed across four priority areas:
- Accelerate commercial deployments with US health systems
- Support pilot programmes and platform integration
- Expand presence in Australia and Europe
- Working capital for operational execution
The emphasis on commercial deployments rather than research and development suggests HeraMED has progressed beyond proof-of-concept and is now focused on scaling adoption. Pilot programmes typically serve as proof points before broader system-wide rollouts, meaning successful pilots could lead to expanded contracts with existing partners. Platform integration work likely involves technical development to ensure HeraCARE connects seamlessly with electronic health record systems used by partner organisations.
For investors, the capital deployment strategy indicates near-term commercial milestones should be forthcoming. Unlike early-stage biotechnology companies where capital funds multi-year clinical trials, this funding directly supports revenue-generating activities with existing commercial partners.
The next major ASX story will hit our subscribers first
Looking ahead: key milestones for 2HFY26
The second half of financial year 2026 represents a critical execution period for HeraMED as fresh capital enables accelerated commercial activity. Management has highlighted the US market as the primary focus, supported by secondary expansion in Australia and Europe.
Key priorities and milestones to monitor include:
- Broader deployment progress with Lee Health partnership
- Philips platform integration completion and commercialisation timeline
- Additional health system pilots converting to commercial agreements
- Shareholder meeting on 16 March 2026 for Tranche 2 approval
The US market focus reflects both opportunity size and healthcare system dynamics. American maternity care faces well-documented challenges around access, cost, and outcomes, creating demand for solutions that can improve efficiency without compromising clinical quality. HeraMED’s reference to “long-standing gaps in care and fragmented solutions” positions the platform as addressing systemic issues rather than competing primarily on price.
Investors should watch for announcements indicating commercial traction, such as expanded patient numbers within existing partnerships, new health system agreements, or regulatory clearances in additional markets. The company’s ability to convert pipeline opportunities into signed agreements will provide evidence of platform scalability and market acceptance, validating the investment thesis behind this capital raising.
Want More Biotech Breakthroughs Like This?
HeraMED’s capital raising highlights the type of execution-stage opportunities emerging across Australia’s digital health and biotech landscape. As companies transition from development to commercial deployment, identifying which platforms gain genuine healthcare system traction becomes critical for informed investment decisions.
The Big News Blast from StockWire X delivers breaking ASX announcements and detailed analysis across biotech, healthcare, technology, and other non-resource sectors—completely free. With over 20,000+ active subscribers, this daily alert service provides the context needed to assess commercial milestones, capital raisings, and partnership developments as they unfold. Simply click the “Free Alerts” button at the top of this page to join investors tracking the next wave of ASX healthcare innovation.